WO2000006651A1 - Complexe ionique, materiau de revetement et procede de revetement - Google Patents
Complexe ionique, materiau de revetement et procede de revetement Download PDFInfo
- Publication number
- WO2000006651A1 WO2000006651A1 PCT/JP1999/004021 JP9904021W WO0006651A1 WO 2000006651 A1 WO2000006651 A1 WO 2000006651A1 JP 9904021 W JP9904021 W JP 9904021W WO 0006651 A1 WO0006651 A1 WO 0006651A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- water
- polyion
- soluble
- insoluble
- ion complex
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0035—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using a polymer with positively charged atoms in the polymeric backbone, e.g. ionenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/062—Mixtures of macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D201/00—Coating compositions based on unspecified macromolecular compounds
- C09D201/02—Coating compositions based on unspecified macromolecular compounds characterised by the presence of specified groups, e.g. terminal or pendant functional groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/31—Surface property or characteristic of web, sheet or block
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/31504—Composite [nonstructural laminate]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/31504—Composite [nonstructural laminate]
- Y10T428/31855—Of addition polymer from unsaturated monomers
Definitions
- the present invention relates to a (poly) ion complex having excellent characteristics of being insoluble in water and soluble in a water-containing organic solvent.
- the ion complex of the present invention utilizes various properties of ionic substances (for example, anticoagulants), which have conventionally been difficult to coat while making the most of their properties while effectively exhibiting their functions. It can be suitably used for coating various substances and substrates (for example, medical materials) with substances having physiological activities such as blood properties and antibacterial properties.
- ionic substances for example, anticoagulants
- the ion complex or the coating material of the present invention, the coated body of the ion complex, or the coating method can be applied to various kinds of base materials, a field of coating on the surface of a substrate, In particular, in fields where it is required to form a coating having excellent coating properties while effectively exhibiting the function of the ionic components constituting the complex (for example, medical applications, electronic materials, charging, etc.).
- the present invention can be applied without particular limitation to the field of prevention materials, etc., but here, first, the background art relating to the ion complex of the present invention in the form of imparting the anticoagulant property together with the coating property will be described. .
- Heparin is an anticoagulant derived from living organisms, and is a mucopolysaccharide with many negative charges based on sulfate groups. The heparinization methods that have been studied conventionally can be roughly classified into the following three types.
- Simple blending method A method in which heparin is simply mixed into resin. According to this method, for example, a material in which heparin is mixed in an epoxy resin is said to have good anticoagulant properties, but there is no bond between the polymer matrix and the heparin. However, there is a drawback that heparin easily falls off in the blood and the anticoagulant property cannot be maintained for a long time.
- Covalent bonding method A method in which heparin is chemically immobilized on the surface of the material to be coated by covalent bonding using a functional group of heparin.
- the amount of heparin immobilized by this method is only about 0.1 g / cm 2 .
- heparin is denatured by chemical reaction or heparin is not released from the coated material, its anticoagulant activity is insufficient, and a satisfactory anticoagulant material can be obtained at present. Not.
- Ion-bonding method A method that uses heparin's negative charge to electrostatically immobilize heparin on the surface of a positively charged material, and provides the best anticoagulant property. It is said that.
- a quaternary ammonium salt type surfactant such as benzalkonium chloride (BC) or tridodecylmethylammonium chloride (TDMAC) is adsorbed on the surface of the material to be coated. Introducing a positive charge to the surface of the material;
- a method is known in which a water-insoluble polycation having a quaternary ammonium group in a main chain or a side chain is coated on the surface of a coated material to introduce a positive charge to the surface of the material.
- the hydrophobic groups of BC and TDMAC are adsorbed on the surface side of the material to be coated in water, and the hydrophilic quaternary nitrogen is arranged outward. It is possible to introduce dimensionally high-density positive charges, and by contacting with a heparin aqueous solution, it is possible to bond parion to the surface of the material to be coated by ion bonding.
- the ion complex of parin is known to dissolve in some organic solvents, and the ion complex can be coated by a solvent cast method (Atha, D., et al.). al., Proc. Nat. Acad, of Sci., 8 1, 10 3 0 — 1 0 3 4 (1 9 8 4)) o
- the heparin-coated material obtained by the method a) is actually used in blood, BC and TDMAC adsorbed on the surface of the material to be coated are low. Since it is a molecule, it has the disadvantage that it is eluted into the blood with heparin. When these cationic surfactants elute, the cationic surfactant causes problems such as hemolysis and aggregation of plasma proteins. In addition, when such a heparin 'coating material is used, there is a problem that heparin flows out early because heparin is bonded only on the surface.
- Anthron (registered trademark; manufactured by Toray Industries, Inc.) is known as a material having good anticoagulant properties.
- This material synthesizes a graft copolymer in which a side chain consisting of a random copolymer of a cationic monomer and a hydrophilic monomer is bonded to the main chain of polyvinyl chloride. Heparin occluded and shows anticoagulant properties by sustained release of heparin of more than 0.01 unit / cm 2 ⁇ min in contact with blood (Mori, Y., et al. , Trans. Am. So Artif. Intern. Organs, 24, 7 3 6 (1 9 7 8
- the heparin 'coating material obtained by this method the elution of substances other than heparin is suppressed.
- the water-insoluble polycation is previously coated on the material surface by a solvent casting method, etc. After evaporating, it was necessary to immerse it in a high-concentration heparin aqueous solution for a long time to form a complex with heparin. Such a process not only requires labor and time, but also has a problem that expensive heparin must be excessively used.
- a polymer of a quaternary ammonium salt monomer having a polymerizable functional group and a hydrocarbon chain having 10 or more and less than 30 carbon atoms and a heparin ion pair form a surface in contact with blood.
- a heparinized material characterized by being adsorbed on a surface is disclosed (Japanese Patent Application No. 6-162210, Japanese Patent Application Laid-Open No. 7-265405). In this case, the elution can be prevented by polymerizing the cationic surfactant.
- the cationic monomer and heparin ion pair are soluble in organic solvents, but the cationic cationic polymerized polycation and heparin ion complex are insoluble in any solvent. Thus, coating by the solvent cast method was not possible.
- An object of the present invention is to provide an ion complex that has solved the above-mentioned disadvantages of the prior art.
- Another object of the present invention is to provide a water-insoluble and water-soluble organic solvent. It is in providing complex.
- Still another object of the present invention is to suitably use the coating of various ionic substances (for example, substances having physiological activities such as anticoagulant and antibacterial properties) (for example, coating of medical materials).
- An object of the present invention is to provide a possible coating material, a coated body of the coating material, and a coating method.
- the inventor has found that the ion complex having the above properties has excellent properties as a coating material for various ionizable substances, and is extremely effective in solving the above-mentioned conventional problems. I saw something interesting.
- the ion complex of the present invention is based on the above findings, and more specifically, is an ion complex composed of a water-insoluble polyion (P) and a water-soluble polyion (A). It is water-insoluble and soluble in a water-containing organic solvent.
- the coating material further includes a coating material and a coating layer covering at least a part of the surface of the coating material, and the coating layer is made of a water-insoluble material.
- An ion complex comprising a polyion (P) of the formula (I) and a water-soluble polyion (A); an ion complex that is insoluble in water and soluble in a water-containing organic solvent.
- a coating body including is provided.
- a water-containing organic solvent is further provided on the material to be coated. Forming a layer of a solution containing the ion complex dissolved in the solvent, and evaporating the aqueous organic solvent to form a coating layer containing the ion complex on the material to be coated.
- a coating method wherein the ion complex comprises a water-insoluble polyion (P) and a water-soluble polyion (A); and is compatible with a water-insoluble and water-containing organic solvent.
- a coating method is provided that is soluble o
- a coating material containing a powdery ion complex is attached to a material to be coated, and the ion complex is swollen with a water-containing organic solvent.
- a coating method comprising a water-soluble polyion (A) and a water-soluble polyion (A); and a water-insoluble organic solvent.
- a polyelectrolyte complex consisting of a polycation and a polyanion (usually called a (poly) ionic complex or a polyelectrolyte complex) is a strong intermolecular complex. It is known that by its action, it forms aggregates that are insoluble in any solvent (E. Tsuchida and K. Abe, "Interaction between Macromolecules in Solution and In termacromolecular Complexes", Springer-Ver 1 ag, 198 82) 0 Therefore, it has been virtually impossible to coat such an ion complex with a solvent in the past, and therefore, it is difficult to use the conventional ion complex for practical use. However, there were various difficulties.
- the step of adsorbing on the surface of the coating-fixed material to be coated had to be separated.
- the ion complex of the present invention comprising a water-soluble polyion (A) and a water-insoluble polyion (P) is water-insoluble and contains water. Since it has the property of being soluble in organic solvents, it can be easily coated on various substrates and substrates (for example, solvent casting), and can be used for a wide range of substrates and substrates (for example, Medical equipment) Applicable to surfaces.
- the use of the ion complex of the present invention solves the problems of conventional coating materials (for example, heparinized materials). That is, a water-soluble polyion (A), for example, a polyanion having anticoagulant properties (eg, heparin) or a polycation having antibacterial properties (eg, polymixin B) is electrostatically converted to Thus, it can be stably immobilized in the surface layers of various substrates and substrates.
- A water-soluble polyion
- A for example, a polyanion having anticoagulant properties (eg, heparin) or a polycation having antibacterial properties (eg, polymixin B) is electrostatically converted to Thus, it can be stably immobilized in the surface layers of various substrates and substrates.
- aqueous fluid for example, a body fluid such as blood
- an aqueous fluid for example, a body fluid such as blood
- elution of components other than the water-soluble polyion (A) into the body fluid can be prevented.
- Gradually releasing the water-soluble polyion (A) for example, a polyanion having anticoagulant properties or a polycation having antibacterial properties
- a water-soluble polyion (A) is strong, and a water-insoluble polyion (P) and a (poly) ion complex are formed. Elution of the water-soluble polyion from the ion complex is relatively suppressed, and the function (eg, physiological activity) of the complex is stably maintained for a long period of time. It is also possible.
- the ion complex of the present invention since the ion complex of the water-soluble polyion (A) and the water-insoluble polyion (P) is formed in advance, the ion complex in the ion complex is not included in the ion complex.
- the amount of the functional material (polyion (A) and / or polyion (P); for example, a physiologically active substance) can be accurately and arbitrarily controlled.
- the characteristics of the polyion complex with a water-soluble polyion are characterized by the following characteristics.
- Water-soluble, insoluble in organic solvents, and soluble in aqueous organic solvents are characterized by the following characteristics.
- the feature of the ionic complex with heparin in Japanese Patent No. 2131838 is that it is insoluble in water and soluble in organic solvents. Based on such a difference in the properties of the polyion complex from the water-insoluble polyion, the water-soluble polyion complex can be obtained from the polyion complex of the present invention as described later.
- the polyion complex when using a polyion complex composed of a bioactive polyion as one component to design, for example, an antithrombotic material or an antibacterial material, the polyion complex is used. It is considered that the sustained release of polyion having bioactivity from the body into body fluids such as blood is the most important factor for the function expression of the polyion complex.
- heparin on polyanion forms a complex with the antithrombin ⁇ ⁇ in the blood to produce various blood It is believed that it promotes the inhibition of liquid coagulation factors (serine proteases) and exerts anticoagulant activity. It is a polyanion that develops a strong anticoagulant effect only when dissolved in blood (eg, “Chemical Domain-Structure and Function of Mucopolysaccharides”, Supplement No. 83, 19668).
- the action of the amino glycoside antibiotic of a polycation having an antibacterial effect is caused by the fact that the amino glycoside antibiotic having a basic group ion-bonds to the cell membrane of an acidic bacterium. It is thought that it is taken up into cells and binds to liposomes, and is expressed by inhibition of protein synthesis, damage to cell membranes and inhibition of DNA replication, etc., as in the case of heparin. It dissolves in body fluids such as blood and develops a strong antibacterial action for the first time (for example, Hyundai Chemistry, Supplement No. 9, “State-of-the-art in Antibiotic Research”, published by Tokyo Chemical Dojin, 1987) See).
- the physiologically active action of a polyion such as heparin or an antibiotic is expressed only when the polyion is dissolved in blood or body fluid.
- the ability to achieve controlled release of a controlled substance is the most important point of such material design.
- polyion In order to release a water-soluble and physiologically active polyion (A) from the polyion complex of the present invention into blood or body fluids in a controlled process, it is necessary to use polyion. It is preferred that (A) be bound to the water-insoluble polyion (P) by a relatively weak bond. That is, all of the ionic groups of the polyion (A) do not form a binding pair with the ionic groups of the water-insoluble polyion (P), and some of the ionic groups of the polyion (A) Preferably, the groups do not form a binding pair and remain free.
- the polyion complex of the present invention in which part of the ionic group of the polyion (A) remains free without forming a binding pair
- organic solvents for example, ethanol
- the part of the ionic group of the polyion (A) that forms a bonding pair with the ionic group of the polyion (p) is soluble in an organic solvent (e.g., ethanol). Since the portion of the ion (A) having a free ion group is soluble in water, it dissolves the binding pair-forming portion and the free portion coexisting in the polyp- nox complex at the same time.
- a water-containing organic solvent which is a mixture of water and an organic solvent, is required.
- the ion complex of the present invention comprises a water-insoluble polyion (P) and a water-soluble polyion (A), and is water-insoluble and soluble in a water-containing organic solvent. It is an ion complex.
- the formation of the “ion complex” can be confirmed, for example, as follows.
- the presence of the ion complex indicates that the test object is substantially insoluble when immersed in a large excess of distilled water and is dissolved in an NaC1 aqueous solution at a concentration of 2 M (mol / litre). When immersed, it can be confirmed by dissolving (the water-soluble components constituting the complex).
- simple (not ion-complex) polyanions, polycations, or poly-zwitterions can be dissolved in either distilled water or the above NaC1 aqueous solution (if water-soluble). Or it does not dissolve in any of distilled water or the above NaC1 aqueous solution (if water-insoluble).
- a simple mixture of a water-insoluble polyion (which does not form an ion complex) and a water-soluble polyion either of the above-described distilled water and the NaCl aqueous solution is used. Also dissolves.
- Test object for example, ion complex
- Weight W, g
- the test object after drying is W 2 g and the value of (W, -W 2 ) no W, is 0.1 or less
- the “insoluble in distilled water” is used in the present invention. Is determined.
- the value is preferably not more than 0.05 (further preferably not more than 0.01).
- the ion complex of the present invention has a strong "water-insoluble” property. It does not dissolve in distilled water. "
- test object for example, ion complex
- NaC1 aqueous solution The dissolution of the test object (for example, ion complex) in the NaC1 aqueous solution can be confirmed, for example, as follows.
- the confirmation that the polyion complex of the present invention does not substantially dissolve in an organic solvent preferably ethanol
- an organic solvent preferably ethanol
- ethanol such as ethanol, DMSO, or THF
- Test object for example, ion complex It can be confirmed that it is powerful and soluble in a water-containing organic solvent, for example, as follows.
- the water-insoluble polyion (P) used in the present invention is a molecule having at least two or more ionic groups in one molecule.
- the polyion is charged with another water-soluble polyion that satisfies certain conditions based on its electrical or steric properties (for example, a charge of the opposite sign to the water-insoluble polyion as a whole molecule).
- the water-insoluble polyion (P) together with the water-soluble polyion (A) forms an ionic complex that is non-water-soluble and soluble in a water-containing organic solvent.
- the solubility of the water-insoluble poly (P) in water is not particularly limited as long as it can be used. At 37 ° C (total weight of the poly ions and water is 100%), it should be 1% or less, further 0.1% or less (particularly 0.01% or less). I like it.
- the molecular weight of the water-insoluble poly- lyne (P) is not particularly limited, the weight-average molecular weight (Mw) determined by gel permeation chromatography (GPC) is 10,000 to 100,000, and 20,000 to 60000. It is preferably in the range of 100,000 (especially 30,000 to 300,000).
- Mw weight-average molecular weight
- GPC gel permeation chromatography
- the molecular weight Mw is less than 10,000, the formation of an ion complex with the water-soluble polyion (A) becomes insufficient, while if the molecular weight Mw exceeds 100,000, the ionic complex contains water. The solubility in organic solvents is reduced, and the tendency to make solvent coating more difficult.
- a complex of a monocation and a polyanion such as a combination of BC or TDMAC with heparin
- a polyanion such as a combination of BC or TDMAC with heparin
- the conventional ion complex composed of a water-soluble polyion and a water-soluble polyion was insoluble in any solvent.
- the ion complex of the present invention has an important feature that it is insoluble in water and soluble in a water-containing organic solvent.
- the water-insoluble polyion (P) forms a water-insoluble and water-soluble organic solvent-soluble ion complex with the water-soluble polyion (A).
- the water-insoluble polyion (P) there is no particular limitation, but those synthesized by the method described below can be suitably used as the water-insoluble polyion (P). That is, in the presence of a water-soluble polyion (A) dissolved in a water-containing organic solvent, a polymerizable monomer (B) having a charge of the opposite sign to the polyion and a water-insoluble Polyion obtained by copolymerization with the monomer (C) to give the polymer (P) can be suitably used.
- the ion complex formed by previously synthesizing a random copolymer of the monomer (B) and the monomer (C) and mixing this with the (A) is a conventional ion complex. Like other ion complexes, they are insoluble in any solvent.
- the polyion in a water-containing organic solvent, in the presence of a dissolved water-soluble polyion (A), the polyion has the opposite charge to the polyion.
- the polymerizable monomer (B) and the monomer (C) giving the water-insoluble polymer (P) were copolymerized, the resulting ionic complex was soluble in a water-containing organic solvent.
- the copolymer obtained in this manner is not a random copolymer in which the monomer (B) and the monomer (C) are statistically arranged in a random manner, but is a monomer (B). But It is presumed that a block copolymer in which the block enriched by the ion (A) and the block mainly composed of the monomer (C) are linked to each other is obtained.
- the block rich in the monomer (B) in the water-insoluble polymer obtained as described above is a force that forms an ion complex with the polyion (A).
- a block consisting mainly of monomer (C) is linked on both sides of the block, this is an obstacle, and this blockages another polyion (A) / monomer (B) with the ion complex part of the color. It is estimated that aggregation is suppressed. That is, the block rich in the monomer (B) and the ion complex portion of the polyion (A) are separated by a block mainly composed of only the monomer (C).
- the ion complex of a polyion (P) composed of a monomer (B) and a monomer (C) and an ion complex of a water-soluble polyion (A) is soluble in a water-containing organic solvent. It is estimated that
- a compatible organic solvent with water can be used without any particular limitation.
- the organic solvent that can be dissolved in water at an arbitrary ratio can be particularly preferably used, since phase separation does not occur even when the solvent composition changes.
- organic solvents examples include alcohols such as ethanol, methanol, and isopropanol; ketones such as acetate and methylethylketone; Lahydrofuran (THF), acetonitril, dimethylformamide (DMF), dimethylsulfoxide (DMSO) and the like can be used.
- a water-containing organic solvent is used, for example, as a coating solvent for a physiologically active material comprising an ionic complex, or although it may be used as a polymerization solvent for the water-soluble polyion (P), the composition of both is not necessarily the same.
- the type of the organic solvent may be appropriately selected according to the material to be coated.
- a solvent that does not substantially dissolve the material to be coated it is possible to avoid deterioration and deformation of the material to be coated.
- a solvent that dissolves the coating material it becomes possible to improve the adhesiveness between the coating material and the coating material.
- the water content of the water-containing organic solvent can be appropriately set within a range in which the coating material consisting of the ion complex is dissolved, but when the solvent is evaporated after coating, the solvent composition changes. In order to avoid precipitation of the ion complex, it is preferable that the water content is low. More specifically, the water content is usually 5 to 60 wt% (assuming the total weight of water and the organic solvent is 100%), and even 5 to 40 wt% (particularly 5 to 2 wt%). 0 wt).
- the hydrous organic solvent may contain a strong electrolyte neutral salt, but the content is preferably as small as possible. More specifically, it is usually 5 wt% or less (assuming that the total weight of the aqueous organic solvent and the strong electrolyte neutral salt is 100%), and further lwt% or less (particularly 0.1 wt% or less). It is preferable that there is. If the content of the strong electrolyte neutral salt exceeds 5 wt%, the ion complex tends to separate out by phase separation and to dissociate the electrostatically bound ion complex. However, the immobilization of the polyion (P) or (A) tends to be unstable.
- a water-containing organic solvent When a water-containing organic solvent is used as a polymerization solvent for the water-insoluble poly (P), the polymerization is carried out in a state in which the water-soluble poly (A) is dissolved.
- the composition of the water-containing organic solvent may be appropriately selected depending on the solubility and concentration of the ion (A). When the water content of the water-containing organic solvent increases, the solubility of the water-soluble polyion (A) increases, so that the polymerization reaction can be performed in the presence of a high concentration of the water-soluble polyion (A). .
- the solubility of the formed ion complex becomes low, the polymerization reaction becomes heterogeneous, the molecular weight of the produced polymer becomes small, and the molecular weight distribution tends to become wide. This tends to make it difficult to obtain a coating material having good film forming properties. Therefore, when a water-containing organic solvent is used as a polymerization solvent for the water-insoluble polyion (P), the water content is usually 10 to 80 wt%, more preferably 40 to 70 wt% (particularly 50 to 70 wt%). ⁇ 65 wt%).
- the water-soluble polyion (A) in the present invention is a molecule having at least two or more ionic groups in one molecule.
- the water-soluble polyion (A) is capable of forming an ion complex that is non-water-soluble and soluble in a water-containing organic solvent with the water-insoluble polyion (P) described above. Can be used without any particular restrictions.
- the solubility of the water-soluble polyion (A) in water is 1% or more at 37 ° C (assuming the total weight of the polyion and water is 100%), and more preferably 5%. % Or more (especially 10% or more) is preferable.
- the molecular weight of the water-soluble polyion (A) is not particularly limited, the weight-average molecular weight (Mw) by GPC is from 200 to 100,000, It is preferably in the range of 100,000 to 100,000 (particularly, 10,000 to 100,000).
- the water-soluble polyion (A) may be, for example, polyione (which has a negative charge as a whole molecule; the same applies hereinafter), polycation ( A substance having a positive charge as the whole molecule, the same applies hereinafter), or an amphoteric electrolyte, or a synthetic, semi-synthetic, or natural product Can be used without any particular limitation.
- polyione which has a negative charge as a whole molecule; the same applies hereinafter
- polycation A substance having a positive charge as the whole molecule, the same applies hereinafter
- an amphoteric electrolyte or a synthetic, semi-synthetic, or natural product
- a synthetic, semi-synthetic, or natural product Can be used without any particular limitation.
- a physiological activity one having the above-mentioned water-insoluble polyion (P) and at least one of the water-soluble polyion (A) having a physiological activity is used.
- the physiological activity that the water-soluble polyion (A) can have is not particularly limited.
- anticoagulant, antibacterial, cell proliferative, antitumor properties and the like can be mentioned.
- physiologically active polyanion examples include acrylic acid and 2-acrylamide disclosed in Japanese Patent Application Laid-Open No. HEI 8-191888, which have anticoagulant properties.
- DO2-Methylpropanesulfonic acid copolymer various sulfated polysaccharides such as dextran sulfate and the like.
- Heparin a natural mucopolysaccharide, is particularly preferably used as a polyanion having anticoagulant properties.
- polyanion having an antibacterial activity as a physiological activity examples include antibiotics having a plurality of acidic groups, such as Benicillin N, Cephalosporin C, and Cephabasin.
- Other bioactive polyanions include nucleic acids such as DNA and RNA, alginic acid, hyaluronic acid, etc. Acidic proteins such as acidic polysaccharides, collagen, and albumin.
- physiologically active polycations include aminoglycoside antibiotics such as kanamycin, gentamicin, and neomycin; chlorhexidine hydrochloride (hibitene); and polymixin.
- aminoglycoside antibiotics such as kanamycin, gentamicin, and neomycin
- chlorhexidine hydrochloride (hibitene) chlorhexidine hydrochloride (hibitene); and polymixin.
- basic organic antibacterial agents such as B and basic polysaccharides such as chitosan.
- the polymerizable monomer (B) having a charge opposite to that of the water-soluble polyion (A) has a polymerizable functional group and a group capable of forming an ion pair with the water-soluble polyion (A).
- a polymerizable functional group As long as it is a monomer that is soluble in a water-containing organic solvent, it can be used without any particular limitation, but is preferably a water-soluble monomer having little steric hindrance.
- the polymerizable functional group include a vinyl group, a (meth) acryl group, a (meth) acrylamide group, and the like.
- Examples of the group capable of forming an ion pair with the water-soluble polyion (A) include, for example, a cationic group (for example, a 1, 2, 3, or quaternary nitrogen group), or an anionic group ( Examples thereof include a carboxyl group, a sulfonate group, and a phosphate group.
- a cationic group for example, a 1, 2, 3, or quaternary nitrogen group
- an anionic group examples thereof include a carboxyl group, a sulfonate group, and a phosphate group.
- polymerizable cationic monomer for example, a polymerizable cationic surfactant having a long-chain alkyl group as disclosed in JP-A-7-265405 can be used, but from the viewpoint of polymerizability.
- a cation monomer having less steric hindrance can be suitably used than a cation monomer having a group having such a large steric hindrance.
- Examples of such a cationic monomer having little steric hindrance include dimethylaminoethyl.
- Water-soluble cationic monomers such as (acryl) acrylamide and its quaternary compound, vinyl pyridin and its quaternary compound are preferably usable.
- examples of the polymerizable anionic monomer include (meth) acrylic acid, itaconic acid, (anhydrous) maleic acid, vinyl sulfonic acid, and styrene sulfonic acid.
- the amount ratio between the polymerizable monomer and the water-soluble polyion (A) is determined based on the point that good biocompatibility is easily obtained, because the anionic group and the cationic group are equimolar, or the anionic group. It is preferable that the excess be used. More specifically, the molar ratio [anionic group] / [cationic group] is preferably in the range of 1 to 3, more preferably 1.1 to 2. If the ratio of [anionic group] / [cationic group] is less than 1, the obtained coating material becomes cationic and the biocompatibility tends to decrease. On the other hand, when the ratio exceeds 3, the solubility of the obtained coating material in the aqueous organic solvent tends to decrease. (Monomer giving water-insoluble polymer (P))
- the monomer (C) that gives the water-insoluble polymer (P) is a monomer that is soluble in a water-containing organic solvent, and the polymer is soluble in a water-containing organic solvent and becomes water-insoluble. It can be used without any restrictions.
- Examples of such a monomer (C) include (meth) acrylic acid esters such as ethyl (meth) acrylate and t-butyl (meth) acrylyl amide. N-substituted (meta) acrylamides can be used. From the viewpoint that the water content of the water-containing organic solvent used as the polymerization solvent can be set high, the monomer is preferably water-soluble. As such a water-soluble monomer (C), for example, 2-hydroxyethyl methacrylate or diacetonitrile amide can be suitably used.
- the monomer (C) that gives the water-insoluble polymer (P) may be a single monomer or a combination of several monomers. When several monomers are used in combination, the copolymerization results As long as the resulting polymer is water-insoluble, even a monomer that gives a water-soluble polymer by homopolymerization can be used depending on the combination with other monomers.
- vinylpyrrolidone or polyethylene glycol (meth) acrylate which gives a water-soluble polymer in homopolymerization, can be used after being copolymerized with other monomers. .
- the water-soluble polymer (A) and the polymerizable monomer (B) having the opposite sign to the water-soluble polymer (A) are copolymerized with the monomer (C) to give the water-insoluble polymer (P).
- the reactive polyion (P) can be obtained, but the copolymerization ratio of the monomer (B) and the Z monomer (C) is usually 1 to 20 wt%, and more preferably 2 to 15 wt% (particularly It is preferably in the range of 5 to 1 O wt%).
- the amount of water-soluble polyion (A) that can be fixed by ionic bonding becomes insufficient, and the water-soluble polyion is insufficient.
- one type of ion complex may be used alone or a different type of ion complex may be used as long as it is water-insoluble and soluble in a water-containing organic solvent. You may mix and use a plurality. For example, if a mixture of an ion complex having anticoagulant properties and an ion complex having antibacterial properties is used, a coating material which simultaneously exhibits anticoagulant properties and antibacterial properties can be obtained. When a mixture of different types of ion complexes is used, it is improper to mix different types of ion complexes (polyanions and polycations) with different signs of the ion complex (total charge in the ion complex).
- all ion complexes have the same sign, as they may form soluble ion complexes. From the viewpoint of biocompatibility, it is preferable that the sign of the ion complex is "negative charge" for which the compatibility is usually considered to be good.
- an ion complex composed of a water-insoluble polycation and a water-soluble polyione (generally negatively charged), and a water-insoluble polycation and a water-soluble polyione are used.
- Ionic complex (negatively charged) composed of a neutral polycation is dissolved in a water-containing organic solvent, and after mixing the respective solutions, the water-containing organic solvent is evaporated. It is possible to obtain an ion complex (or a coating material) that mixes different types of ion complexes.
- the ion complex or the coating material of the present invention can be used in a form to exhibit its own function, for example, it can be used as various medical materials by itself. As long as expression is possible, it may be used by being localized on the surface of another material. For example, when the ion complex or the coating material of the present invention is used as a medical material, it is sufficient that the complex material is localized only on the surface that comes into contact with the living body. It can be used by coating a medical material molded from metal, plastic, etc.) on the surface that comes into contact with the living body.
- the coating method that can be used for the complex / material of the present invention is not particularly limited.
- the material to be coated is immersed in a solution in which the ionic complex of the present invention is dissolved in a water-containing organic solvent, or the coating method is used.
- the solution of the present invention is applied by applying the solution to the material to be coated and evaporating the water-containing organic solvent (so-called solvent casting method). It is possible to suitably coat the coating material.
- the ion complex (coating material) of the present invention is powdered and adhered to the material to be coated, and the ion complex is swollen with a water-containing organic solvent. Thereafter, the aqueous organic solvent can be evaporated to coat the ion complex.
- the dry complex of the present invention may be mechanically pulverized, or the solvent composition may be obtained by dissolving it in a water-containing organic solvent.
- the temperature or changing the temperature fine particles may be precipitated (chemical pulverization) and powdered.
- the material to be coated may be moistened with a solvent to adhere the powder.
- the electrostatic coating method is preferred. It can be used particularly preferably.
- the coating material of the present invention contains at least an ion complex composed of the above-mentioned water-insoluble polyion (P) and a water-soluble polyion (A).
- the coating material may contain other additives or third components as needed (within a range that does not substantially impair the function of the ion complex).
- Such an additive or third component examples include a component that imparts lubricity to the coating surface (such as teflon particles) and a component that imparts abrasion resistance to the coating layer (eg, metal). And a component (plasticizer, etc.) that imparts flexibility to the coating layer.
- the ion complex or the coating material of the present invention can be used by being coated on various substrates and substrates as necessary.
- the material, shape, surface condition, etc. of such a substrate or substrate No particular limitation is imposed on the ion complex or the coating material of the present invention as long as the material can be coated.
- the material include a metal, a plastic, a ceramic, and a composite material.
- the above shape include a sheet shape, a powdery or granular shape, a fiber shape, a cylindrical shape (hollow or solid; for example, a catheter shape), a net shape (for example, a stent shape), and the like.
- Examples of the above surface state include an uneven surface (rough surface), a smooth surface, a combination thereof, and the like.
- the ion complex or the coating material of the present invention is used as a medical material, as described above, the ion complex or the coating material is localized only on the contact surface with the living body. Or just scatter them.
- Diacetone acrylamide (DAC AM, manufactured by Kyowa Hakko Co., Ltd.) 2.0 g, polyethylene glycol monomethacrylate (PME 400, average molecular weight 4,000) 0, manufactured by Nippon Yushi Co., Ltd.) 0.14 g, 75% aqueous solution of methyl chloride quaternary N, N-dimethylaminopropylacrylamide (DMA PAAQ (aq), Inc.) 0.19 g (produced by Kojin) and 0.14 g of heparin sodium (produced by Wako Pure Chemical Industries, Ltd.) were dissolved in 7.5 g of distilled water.
- DMA PAAQ methyl chloride quaternary N, N-dimethylaminopropylacrylamide
- a coating material (1) comprising the ion complex of the present invention.
- the above-mentioned coating material (1) was insoluble in distilled water and insoluble in ethanol, but was soluble in hydrated ethanol.
- the coating material (1) solution (8 wt%) was applied (approximately 1.6 ml) onto a polyurethane sheet (5 cm ⁇ 5 cm, thickness 1 mm) as a material to be coated, and the solvent was applied. Was evaporated. Due to the weight increase after the vacuum drying of the coated polyurethane sheet, the coating material
- the coating amount of (1) was determined to be I 25 mg (coating thickness: about 50 ⁇ .
- the coating was immersed in distilled water at 37 ° C. for 24 hours.
- the moisture content of the coating layer was determined from the subsequent weight increase to be 36 wt%, and the coating amount was determined again from the weight measurement after vacuum drying, and the measured value was 1 No change was observed at 25 mg.
- Diacetone acrylamide (DACAM, manufactured by Kyowa Hakko Co., Ltd.) 2.0 g, Polyethylene glycol monomethacrylate (PME 400 000, average molecular weight 4.0 000) 0.14 g, 75% aqueous solution of N, N-dimethylaminopropylpyranoleamide, methyl chloride quaternary (D MA PAAQ (aq), Koyo Co., Ltd.) Human) 0. 19 g and 0.28 g of heparin sodium (manufactured by Wako Pure Chemical Industries, Ltd.) were dissolved in 9 g of distilled water.
- DACAM Diacetone acrylamide
- PME 400 000 Polyethylene glycol monomethacrylate
- PME 400 000 Average molecular weight 4.0 000
- D MA PAAQ methyl chloride quaternary
- the above coating material (2) was insoluble in distilled water and insoluble in ethanol, and was soluble in hydrated ethanol.
- 0.2 g of the coating material (2) was dissolved in 2.3 g of water-containing ethanol (water content: 33 wt%), a completely viscous solution was obtained.
- the concentration of the coating material (2) was 8 wt%).
- the coating material (2) solution (8 wt%) was applied (approximately 1.6 ml) on a polyurethane sheet (5: 115.111, thickness: 1111111), and the solvent was removed. Evaporated. From the weight increase after vacuum drying, the coating amount of the coating material (2) was 125 mg (coating thickness: about 50 ⁇ m). The water content of the coating layer was found to be 42 wt% from the increase in weight after immersion in distilled water at 37 ° C. for 24 hours. From the weight measurement after vacuum drying, no change was observed with the coating amount remaining at 125 mg.
- Diacetone acrylamide (DACAM, manufactured by Kyowa Hakko Co., Ltd.) 2.0 g, N, N—Dimethylaminopropylacrylamide, methyl chloride quaternary 75% aqueous solution (DMA PAAQ (aq), manufactured by Kojin Co., Ltd.) 0.19 g, 0.28 g of heparin sodium and heparin sodium (manufactured by Wako Pure Chemical Industries, Ltd.) were dissolved in 9 g of distilled water.
- DMA PAAQ aq
- the residue After sufficiently washing the residue with distilled water, the residue is thoroughly washed again with distilled water (three times with about 10 O ml), freeze-dried while keeping the water-containing state, and coated with the coating material of the present invention ( 3) 2.3 g were obtained.
- the above-mentioned coating material (3) was insoluble in distilled water and insoluble in ethanol, but was soluble in hydrous ethanol. Coating material
- the coating material (3) solution (8 wt%) was applied (approximately 1.6 ml) to a polyurethane sheet (5 cm 5 cm, thickness l mm), and the solvent was evaporated. From the increase in weight after vacuum drying, the coating amount of the coating material (3) was 125 mg (coating thickness).
- the water content of the coating layer was found to be 40 wt% from the increase in weight after immersion in distilled water at 37 ° C for 24 hours. From the weight measurement after vacuum drying, no change was observed with the coating amount remaining at 125 mg.
- Diacetone acrylamide (DACAM, manufactured by Kyowa Hakko Co., Ltd.) 1.6 g, N, N-dimethylaminopropyl acrylamide, methyl chloride quaternary 75% aqueous solution (DMA PAAQ ( aq), 0.19 g of Kojin Co., Ltd., and 0.20 g of heparin sodium (Wako Pure Chemical Industries, Ltd.) were dissolved in 8.5 g of distilled water.
- DMA PAAQ aq
- the obtained residue was sufficiently washed with distilled water (three times with about 10 O ml), and ethanol 50 ml was added to dissolve the residue, and the mixture was dried by an evaporator. After sufficiently washing the residue with distilled water, the residue is thoroughly washed again with distilled water (three times with about 10 O ml), lyophilized while keeping the water-containing state, and coated with the coating material of the present invention ( 4) 2.2 g were obtained.
- the above coating material (4) was insoluble in distilled water and insoluble in ethanol, but soluble in aqueous ethanol.
- Coating material (4) When 0.2 g is dissolved in 2.3 g of water-containing ethanol (water content: 18 wt%), a completely viscous and transparent viscous solution (coating material ( 4) concentration of 8 wt%).
- the coating material (4) solution (8 wt%) was applied (approximately 1.6 ml) onto a polyurethane sheet (5 cm x 5 cm, thickness lmm), and the solvent was evaporated. I let it. From the weight increase after vacuum drying, the coating amount of the coating material (4) was 125 mg (coating thickness: about 50 urn). This was immersed in distilled water at 37 ° C for 24 hours. From the increase in weight, the water content of the coating layer was found to be 37 wt%. Further, from the weight measurement after vacuum drying the same, the amount of coating remained at 125 mg and no change was observed.
- the above-mentioned polyurethane sheet coated with the coating material (4) was immersed in a 0.06% aqueous solution of Tolu Jimble for 1 hour and washed with water.
- the coating material (4) was coated with the coating material (4).
- the tinted polycarbonate sheet was stained purple. That is, it was confirmed that the free anionic group (sulfonate group) of heparin was in excess of the cation group (quaternary amine).
- Example 4 In a polyvinyl chloride tube (inner diameter 3 mm, outer diameter 6 mm), a solution of the coating material (4) obtained in Example 4 in water-containing ethanol (water content: 18 wt%) (coating material (4 )) was circulated at a flow rate of 2 ml Z using a peristaltic pump (roller pump), and then nitrogen gas was passed through it at a flow rate of 10 m 1 to dry it. The coating material was coated on the inner surface of the tube.
- Diacetone Acrylamide (DACAM, manufactured by Kyowa Hakko Co., Ltd.) 1.6 g, Sodium acrylate (Wako Pure Chemical Industries, Ltd.) 0.07 g And 0.2 g of Polymixin B Sulfate (manufactured by Wako Pure Chemical Industries, Ltd.) were dissolved in 8.5 g of distilled water.
- the obtained residue was sufficiently washed with distilled water (three times with about 10 O ml), dissolved in ethanol (5 O ml), and dried by an evaporator. After thoroughly washing the residue with distilled water, the residue is thoroughly washed again with distilled water (three times with about 10 O ml), freeze-dried while keeping the water-containing state, and coated with the coating material of the present invention (5). ) 2.2 g were obtained.
- the above coating material (5) was insoluble in distilled water and insoluble in ethanol, but was soluble in aqueous ethanol.
- Coating material (5) When 0.2 g is dissolved in 2.3 g of water-containing ethanol (water content: 18 wt%), a completely viscous solution (coating material) Material (5) at a concentration of 8 wt%).
- the coating material (5) solution (8 wt%) was applied (about 1.6 ml) on a polyurethane sheet (5 cm ⁇ 5 cm, thickness l mm), and the solvent was evaporated. . From the weight increase after vacuum drying, the coating amount of the coating material (5) was 125 mg (coating thickness: about 50 u). The water content of the coating layer was found to be 37 wt% from the weight increase after immersion in distilled water at 37 ° C for 24 hours. From the weight measurement after vacuum drying, no change was observed with the coating amount remaining at 125 mg.
- DHL inoculated with Escherichia coli (E. coli, ATCC 25922) was cut out from the coated polyurethane sheet of the coating material (5) obtained in Example 6 into a disk having a diameter of 1 cm.
- the coated surface was placed on an agar plate (Difco Plate Agar) by pressing it with sterile forceps.
- DAC AM diacetone acrylamide
- sodium styrenesulfonate manufactured by Wako Pure Chemical Industries, Ltd.
- kanamycin 0.05 g of a semisynthetic antibiotic dibekacin sulfate manufactured by Meiji Seika Co., Ltd.
- APS ammonium persulfate
- TE MED N, N, ', N'-tetramethylethylene diamine
- the coating solution is subjected to solvent casting on a polyethylene film at room temperature (25 ° C), dried at room temperature for 24 hours, and separated from the polyethylene film to remove the composition film (5 cm in size).
- X 5 cm and a thickness of about 70 j were prepared.
- composition film to which dibekacin was bound was prepared.
- the composition film was insoluble in distilled water and in ethanol, but soluble in aqueous ethanol.
- Example 8 After the coating film obtained in Example 8 was cut into a rectangle having a side of about 0.5 cm, each was placed in a large amount of physiological saline (about 1000 m 1) at room temperature. Time (30 minutes, 3 hours, 8 hours, 1 day, 3 days, 1 week, 2 weeks, and 26 days) After immersion, place on Bacillus subtilis inoculated DHL agar plate (Difco Plate Agar) The coating surface of the film was pressed down using sterile tweezers.
- the cells are cultured at 32 to 35 ° C overnight (approximately 24 hours), and then measured in a large amount of physiological saline each time by measuring the width of the growth inhibition zone formed around the film. The effect of the immersion operation on the antibacterial activity of the film was measured.
- a water-insoluble polyion (P) and a water-soluble polyion (A) are combined with an ion complex to form an ion.
- an ion complex which is insoluble in water and soluble in a water-containing organic solvent is provided.
- the coating material further includes a coating material, and a coating layer that covers at least a part of the surface of the coating material, and the coating layer is water-insoluble.
- An ion complex comprising a polyion (P) of the formula (I) and a water-soluble polyion (A); a coating comprising an ion complex that is insoluble in water and soluble in a water-containing organic solvent. Body is provided.
- a layer of a solution containing a water-containing organic solvent and an ion complex dissolved in the solvent is further formed on the material to be coated, and the water-containing organic solvent is evaporated to form a layer of the solution.
- P water-insoluble poly ion
- a coating method is provided which is insoluble in water and soluble in a water-containing organic solvent.
- the coating method further comprises a powdery ion complex.
- the coating material is adhered to the material to be coated, the ionic complex is swollen with a water-containing organic solvent, and the water-containing organic solvent is evaporated to form an ion-conducting material on the material to be coated.
- a coating method that is water-soluble and soluble in a water-containing organic solvent is provided.
- the ionic complex of the present invention comprising the water-soluble polyion (A) and the water-insoluble polyion (P) is soluble in a water-containing organic solvent, it can be coated on various substrates and substrates.
- One ting for example, Solve Can be easily applied to a wide range of substrates and substrates (eg, medical devices) made of various materials.
- a water-soluble polyion (A) for example, a polyanion having anticoagulant properties (eg, heparin) or a polycation having antibacterial properties (eg, polymixin B) is electrostatically converted into Various substrates, substrates (for example, medical devices) can be stably immobilized in the surface layer. Further, the coating surface comes into contact with a body fluid such as blood, thereby effectively suppressing the elution of components other than the water-soluble polyion (A) into the body fluid. It is possible to gradually release ions (A) (polyanion having anticoagulant properties and polycations having antibacterial properties) into the body fluid.
- ions (A) polyanion having anticoagulant properties and polycations having antibacterial properties
- the water-soluble polyion (A) is strong and forms a (poly) ion complex with the water-insoluble polyion (P). Since it is also possible to relatively suppress the elution of the conductive polyion, the function (for example, physiological activity) of the complex can be stably maintained for a long period of time.
- the ion complex of the present invention since the ion complex of the water-soluble polyion (A) and the water-insoluble polyion (P) is formed in advance, the ion complex in the ion complex
- the amount of the functional material (polyion (A) and Z or polyion (P); for example, a physiologically active substance) can be accurately and arbitrarily controlled.
- the coating method of the present invention it is possible to easily coat the above-described ion complex on various substrates and the surfaces of the substrates.
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU49283/99A AU4928399A (en) | 1998-07-27 | 1999-07-07 | Ion complex, coating material, and coating method |
DE69920391T DE69920391T2 (de) | 1998-07-27 | 1999-07-27 | Ion-komplex, beschichtungsmaterial, und beschichtungsverfahren |
AT99933116T ATE277126T1 (de) | 1998-07-27 | 1999-07-27 | Ion-komplex, beschichtungsmaterial, und beschichtungsverfahren |
EP99933116A EP1020495B1 (en) | 1998-07-27 | 1999-07-27 | Ion complex, coating material, and coating method |
JP2000562439A JP3705740B2 (ja) | 1998-07-27 | 1999-07-27 | イオンコンプレックス、コーティング体およびコーティング方法 |
US09/535,532 US6555225B1 (en) | 1998-07-27 | 2000-03-27 | Ion complex, coated product and coating method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21100898 | 1998-07-27 | ||
JP10/211008 | 1998-07-27 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/535,532 Continuation US6555225B1 (en) | 1998-07-27 | 2000-03-27 | Ion complex, coated product and coating method |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000006651A1 true WO2000006651A1 (fr) | 2000-02-10 |
Family
ID=16598815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/004021 WO2000006651A1 (fr) | 1998-07-27 | 1999-07-27 | Complexe ionique, materiau de revetement et procede de revetement |
Country Status (7)
Country | Link |
---|---|
US (1) | US6555225B1 (ja) |
EP (1) | EP1020495B1 (ja) |
JP (1) | JP3705740B2 (ja) |
AT (1) | ATE277126T1 (ja) |
AU (1) | AU4928399A (ja) |
DE (1) | DE69920391T2 (ja) |
WO (1) | WO2000006651A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007506826A (ja) * | 2003-09-25 | 2007-03-22 | ロディア・シミ | 表面改質剤又は表面処理剤としての複合体コアセルベートコアミセル |
JP2009515970A (ja) * | 2005-11-15 | 2009-04-16 | ボストン サイエンティフィック リミテッド | 治療薬結合が増強された医療用製品 |
WO2013027556A1 (ja) * | 2011-08-22 | 2013-02-28 | テルモ株式会社 | 抗血栓性材料および医療用具 |
WO2013136849A1 (ja) * | 2012-03-13 | 2013-09-19 | テルモ株式会社 | 血液適合性材料および医療用具 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7226968B2 (en) * | 2003-05-20 | 2007-06-05 | Arch Uk Biocides Limited | Composition and use |
US7217759B2 (en) * | 2003-05-20 | 2007-05-15 | Arch Uk Biocides Limited | Composition and use |
US20060212106A1 (en) * | 2005-03-21 | 2006-09-21 | Jan Weber | Coatings for use on medical devices |
US20070243237A1 (en) * | 2006-04-14 | 2007-10-18 | Mazen Khaled | Antimicrobial thin film coating and method of forming the same |
US8049061B2 (en) | 2008-09-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Expandable member formed of a fibrous matrix having hydrogel polymer for intraluminal drug delivery |
US8500687B2 (en) | 2008-09-25 | 2013-08-06 | Abbott Cardiovascular Systems Inc. | Stent delivery system having a fibrous matrix covering with improved stent retention |
US8226603B2 (en) | 2008-09-25 | 2012-07-24 | Abbott Cardiovascular Systems Inc. | Expandable member having a covering formed of a fibrous matrix for intraluminal drug delivery |
US8076529B2 (en) | 2008-09-26 | 2011-12-13 | Abbott Cardiovascular Systems, Inc. | Expandable member formed of a fibrous matrix for intraluminal drug delivery |
US20100285085A1 (en) * | 2009-05-07 | 2010-11-11 | Abbott Cardiovascular Systems Inc. | Balloon coating with drug transfer control via coating thickness |
US9033956B2 (en) * | 2011-09-06 | 2015-05-19 | Cook Medical Technologies Llc | Electrically charged medical device |
RU2679615C1 (ru) * | 2013-11-28 | 2019-02-12 | Торэй Индастриз, Инк. | Антитромботический материал |
KR102370116B1 (ko) | 2014-05-09 | 2022-03-04 | 도레이 카부시키가이샤 | 혈관내 치료 보조구 |
US20170354756A1 (en) * | 2014-11-18 | 2017-12-14 | University Of Utah Research Foundation | Polyphosphate hydrogels and methods of making and using thereof |
EP3305342A4 (en) * | 2015-05-27 | 2019-02-06 | Toray Industries, Inc. | ANTITHROMBOTIC MATERIAL |
CN109844005B (zh) | 2016-08-24 | 2022-05-10 | 有机点击股份公司 | 具有增加的疏水性的含脂肪族化合物的生物基聚电解质络合物组合物 |
SE1651136A1 (en) | 2016-08-24 | 2018-02-25 | Organoclick Ab | Bio-based pec compositions as binders for fiber based materials, textiles, woven and nonwoven materials |
JP7131832B2 (ja) * | 2016-08-24 | 2022-09-06 | オルガノクリック アーベー | 非水溶性粒子を含むバイオベースの高分子電解質錯体組成物 |
CN109528767A (zh) * | 2018-12-20 | 2019-03-29 | 江苏经贸职业技术学院 | 一种基于pnipam与银纳米簇抗菌制剂的合成方法 |
EP3725753B1 (de) | 2019-04-15 | 2021-09-29 | PAGEL Spezial-Beton GmbH & Co. KG | Hydrophobierungsmittel für mineralische materialien |
DE102019205395A1 (de) | 2019-04-15 | 2020-10-15 | Ionys Ag | Polyionen-Komplexe |
CA3128304A1 (en) * | 2019-04-18 | 2020-10-22 | Universite De Liege | Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54147696A (en) * | 1978-05-12 | 1979-11-19 | Kogyo Gijutsuin | Antithrombotic elastic body |
JPS6359966A (ja) * | 1986-09-01 | 1988-03-15 | テルモ株式会社 | 抗血液凝固性高分子材料およびその製法 |
JPS63214304A (ja) * | 1987-03-04 | 1988-09-07 | Agency Of Ind Science & Technol | ポリイオンコンプレツクス含有膜の製造方法 |
JPS6475508A (en) * | 1987-09-18 | 1989-03-22 | Kohjin Co | Curable composition |
JPH02298902A (ja) * | 1989-05-12 | 1990-12-11 | Dainippon Printing Co Ltd | 偏光膜及びその製造方法 |
JPH0733682A (ja) * | 1993-07-26 | 1995-02-03 | Shiseido Co Ltd | 新規複合体、それを担体として利用する徐放性製剤 |
JPH08198906A (ja) * | 1995-01-24 | 1996-08-06 | Mitsui Toatsu Chem Inc | アクリルアミド系重合体の製造方法 |
JPH10287711A (ja) * | 1997-04-11 | 1998-10-27 | Unitika Chem Co Ltd | ポリビニルアルコール系含水ゲルの製造方法および酵素・微生物固定化成形物の製造方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6040863B2 (ja) * | 1976-07-02 | 1985-09-12 | 富田製薬株式会社 | 医療用吸着剤 |
JPS60135432A (ja) * | 1983-12-23 | 1985-07-18 | Lion Corp | 改質吸水性樹脂 |
JPS60139743A (ja) * | 1983-12-28 | 1985-07-24 | Toyo Soda Mfg Co Ltd | ポリイオン錯合体均一液およびその製造方法 |
AU566085B2 (en) * | 1984-06-04 | 1987-10-08 | Terumo Kabushiki Kaisha | Medical instrument with surface treatment |
US4871461A (en) * | 1987-01-22 | 1989-10-03 | The General Director Of The Agency Of Industrial Science And Technology | Polymer composite membrane |
JPH0624593B2 (ja) * | 1987-10-22 | 1994-04-06 | 宇部興産株式会社 | 抗血液凝固性材料 |
AU636544B1 (en) * | 1991-11-27 | 1993-04-29 | Lignyte Co., Ltd. | Water insoluble biocompatible hyaluronic acid polyion complex and method of making the same |
US5731087A (en) * | 1995-06-07 | 1998-03-24 | Union Carbide Chemicals & Plastics Technology Corporation | Lubricious coatings containing polymers with vinyl and carboxylic acid moieties |
-
1999
- 1999-07-07 AU AU49283/99A patent/AU4928399A/en not_active Abandoned
- 1999-07-27 DE DE69920391T patent/DE69920391T2/de not_active Expired - Lifetime
- 1999-07-27 EP EP99933116A patent/EP1020495B1/en not_active Expired - Lifetime
- 1999-07-27 JP JP2000562439A patent/JP3705740B2/ja not_active Expired - Lifetime
- 1999-07-27 AT AT99933116T patent/ATE277126T1/de not_active IP Right Cessation
- 1999-07-27 WO PCT/JP1999/004021 patent/WO2000006651A1/ja active IP Right Grant
-
2000
- 2000-03-27 US US09/535,532 patent/US6555225B1/en not_active Expired - Lifetime
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54147696A (en) * | 1978-05-12 | 1979-11-19 | Kogyo Gijutsuin | Antithrombotic elastic body |
JPS6359966A (ja) * | 1986-09-01 | 1988-03-15 | テルモ株式会社 | 抗血液凝固性高分子材料およびその製法 |
JPS63214304A (ja) * | 1987-03-04 | 1988-09-07 | Agency Of Ind Science & Technol | ポリイオンコンプレツクス含有膜の製造方法 |
JPS6475508A (en) * | 1987-09-18 | 1989-03-22 | Kohjin Co | Curable composition |
JPH02298902A (ja) * | 1989-05-12 | 1990-12-11 | Dainippon Printing Co Ltd | 偏光膜及びその製造方法 |
JPH0733682A (ja) * | 1993-07-26 | 1995-02-03 | Shiseido Co Ltd | 新規複合体、それを担体として利用する徐放性製剤 |
JPH08198906A (ja) * | 1995-01-24 | 1996-08-06 | Mitsui Toatsu Chem Inc | アクリルアミド系重合体の製造方法 |
JPH10287711A (ja) * | 1997-04-11 | 1998-10-27 | Unitika Chem Co Ltd | ポリビニルアルコール系含水ゲルの製造方法および酵素・微生物固定化成形物の製造方法 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007506826A (ja) * | 2003-09-25 | 2007-03-22 | ロディア・シミ | 表面改質剤又は表面処理剤としての複合体コアセルベートコアミセル |
JP2009515970A (ja) * | 2005-11-15 | 2009-04-16 | ボストン サイエンティフィック リミテッド | 治療薬結合が増強された医療用製品 |
WO2013027556A1 (ja) * | 2011-08-22 | 2013-02-28 | テルモ株式会社 | 抗血栓性材料および医療用具 |
EP2749302A1 (en) * | 2011-08-22 | 2014-07-02 | Terumo Kabushiki Kaisha | Antithrombogenic material and medical device |
JPWO2013027556A1 (ja) * | 2011-08-22 | 2015-03-19 | テルモ株式会社 | 抗血栓性材料および医療用具 |
EP2749302A4 (en) * | 2011-08-22 | 2015-04-01 | Terumo Corp | ANTI-TURMOUS MATERIAL AND MEDICAL DEVICE |
US9415144B2 (en) | 2011-08-22 | 2016-08-16 | Terumo Kabushiki Kaisha | Antithrombotic material and medical device |
WO2013136849A1 (ja) * | 2012-03-13 | 2013-09-19 | テルモ株式会社 | 血液適合性材料および医療用具 |
Also Published As
Publication number | Publication date |
---|---|
EP1020495A1 (en) | 2000-07-19 |
EP1020495B1 (en) | 2004-09-22 |
US6555225B1 (en) | 2003-04-29 |
ATE277126T1 (de) | 2004-10-15 |
DE69920391T2 (de) | 2006-02-16 |
EP1020495A4 (en) | 2001-10-24 |
JP3705740B2 (ja) | 2005-10-12 |
AU4928399A (en) | 2000-02-21 |
DE69920391D1 (de) | 2004-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000006651A1 (fr) | Complexe ionique, materiau de revetement et procede de revetement | |
US5945457A (en) | Process for preparing biologically compatible polymers and their use in medical devices | |
JP2691854B2 (ja) | 生体活性表面を有する物、抗血栓性かつ感染抵抗性のもの及び皮下埋設可能な物に生体活性表面を与える方法。 | |
JP5178506B2 (ja) | ドラッグデリバリー組成物と関連する方法 | |
EP0597593A1 (en) | Thromboresistant articles | |
Lin et al. | Hemocompatibility of polyacrylonitrile dialysis membrane immobilized with chitosan and heparin conjugate | |
Jayakumar et al. | Graft copolymerized chitosan—present status and applications | |
Okano et al. | Suppression of platelet activity on microdomain surfaces of 2‐hydroxyethyl methacrylate‐polyether block copolymers | |
Gutowska et al. | Heparin release from thermosensitive polymer coatings: in vivo studies | |
JPH05123394A (ja) | 抗血栓性物質の固定化方法 | |
JPH08191888A (ja) | 抗凝血材料及び物品 | |
JP4339413B2 (ja) | 水不溶性ポリマーおよびポリアルキレンイミンの反応混合物を使用した表面改質方法 | |
WO2009029087A2 (en) | Superporous hydrogels | |
JP2001504877A (ja) | 生体適合性の組成物 | |
CN107970792B (zh) | 抗菌防污双功能聚氨酯表面交联复合膜及其制备方法 | |
Chen et al. | Intelligent design and medical applications of antimicrobial hydrogels | |
CN113713183A (zh) | 一种具有优异长效抗凝血及抗菌抗污性能的生物医用涂层及其制备方法 | |
EP0780419A1 (en) | Multi-functional site containing polymers, and applications thereof | |
JP7158993B2 (ja) | ホスホリルコリン基含有共重合体、および生体用医療基材 | |
CN113372494A (zh) | 一种抗凝血聚合物涂层材料及其制备方法 | |
JPS6040863B2 (ja) | 医療用吸着剤 | |
EP1057492B1 (en) | Blood-compatible composition and medical device using same | |
Moon et al. | Improved blood compatibility by sustained release of heparin–deoxycholic acid conjugates in a PCL–PEG multiblock copolymer matrix | |
JPH10151192A (ja) | 抗血栓性組成物および医用材料 | |
Jana et al. | Chitosan-Based Interpenetrating Polymer Networks: Drug Delivery Application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999933116 Country of ref document: EP Ref document number: 09535532 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1999933116 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999933116 Country of ref document: EP |